These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30439589)

  • 1. Viral resistance in HCV infection.
    Ceccherini-Silberstein F; Cento V; Di Maio VC; Perno CF; Craxì A
    Curr Opin Virol; 2018 Oct; 32():115-127. PubMed ID: 30439589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.
    Khaliq S; Raza SM
    Medicina (Kaunas); 2018 Nov; 54(5):. PubMed ID: 30400604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment failure with new hepatitis C drugs.
    Soriano V; Vispo E; Poveda E; Labarga P; Barreiro P
    Expert Opin Pharmacother; 2012 Feb; 13(3):313-23. PubMed ID: 22242928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of resistance in HCV treatment.
    Vermehren J; Sarrazin C
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):487-503. PubMed ID: 23199507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hepatitis C revolution part 1: antiviral treatment options.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of interferon in the new era of hepatitis C treatments.
    Parekh PJ; Shiffman ML
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):649-56. PubMed ID: 24758387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
    Jensen DM; Brunda M; Elston R; Gane EJ; George J; Glavini K; Hammond JM; Le Pogam S; Nájera I; Passe S; Piekarska A; Rodriguez I; Zeuzem S; Chu T;
    Liver Int; 2016 Apr; 36(4):505-14. PubMed ID: 26519669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
    Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
    Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy.
    Alhamlan FS; Al-Ahdal MN; Khalaf NZ; Abdo AA; Sanai FM; Al-Ashgar HI; Elhefnawi M; Zaid A; Al-Qahtani AA
    J Med Virol; 2014 Feb; 86(2):224-34. PubMed ID: 24166351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
    Pawlotsky JM
    Hepatology; 2011 May; 53(5):1742-51. PubMed ID: 21374691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
    Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
    Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.
    Cuypers L; Ceccherini-Silberstein F; Van Laethem K; Li G; Vandamme AM; Rockstroh JK
    Rev Med Virol; 2016 Nov; 26(6):408-434. PubMed ID: 27401933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
    Ji F; Wei B; Yeo YH; Ogawa E; Zou B; Stave CD; Li Z; Dang S; Furusyo N; Cheung RC; Nguyen MH
    Aliment Pharmacol Ther; 2018 Mar; 47(5):550-562. PubMed ID: 29327780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.